Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heinz Wiendl

Showing results (11-20 of 696) with videos related to

Pageof 70
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trialsHeinz Wiendl, Reinhard Hohlfeld
Neurology|September 25, 2009
Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?Olaf Stüve, Heinz Wiendl
Proceedings of the National Academy of Sciences of the United States of America|January 31, 2023
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapyMichael Heming, Heinz Wiendl
Stroke|July 4, 2013
Con: Regulatory T cells are protective in ischemic strokeChristoph Kleinschnitz, Heinz Wiendl
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 6, 2022
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?Julia Krämer, Heinz Wiendl
Current Opinion in Neurology|March 27, 2024
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectationsJulia Krämer, Heinz Wiendl
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 14, 2015
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic ApplicationsStefan Bittner, Heinz Wiendl
The Lancet Regional Health. Europe|October 24, 2024
Emerging trends and challenges in multiple sclerosis in Europe: rethinking classification and addressing COVID-19 impactCatharina Korsukewitz, Heinz Wiendl
Acta Neuropathologica|July 1, 2015
Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous systemBernd C Kieseier, Heinz Wiendl
The Lancet. Neurology|May 17, 2011
Transforming multiple sclerosis trials into practical realityBernd C Kieseier, Heinz Wiendl
Pageof 70

Showing results (11-20 of 696) with videos related to

Sort By:
Pageof 70
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trialsHeinz Wiendl, Reinhard Hohlfeld
Neurology|September 25, 2009
Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?Olaf Stüve, Heinz Wiendl
Proceedings of the National Academy of Sciences of the United States of America|January 31, 2023
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapyMichael Heming, Heinz Wiendl
Stroke|July 4, 2013
Con: Regulatory T cells are protective in ischemic strokeChristoph Kleinschnitz, Heinz Wiendl
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|July 6, 2022
What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?Julia Krämer, Heinz Wiendl
Current Opinion in Neurology|March 27, 2024
Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectationsJulia Krämer, Heinz Wiendl
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 14, 2015
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic ApplicationsStefan Bittner, Heinz Wiendl
The Lancet Regional Health. Europe|October 24, 2024
Emerging trends and challenges in multiple sclerosis in Europe: rethinking classification and addressing COVID-19 impactCatharina Korsukewitz, Heinz Wiendl
Acta Neuropathologica|July 1, 2015
Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous systemBernd C Kieseier, Heinz Wiendl
The Lancet. Neurology|May 17, 2011
Transforming multiple sclerosis trials into practical realityBernd C Kieseier, Heinz Wiendl
Pageof 70